Trial reportAnnals of hematology2019
Thromboembolic events in polycythemia vera.
Trial report in Annals of hematology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Hematologic and molecular response to ropeginterferon alfa-2b in patients with polycythemia vera: a systematic review and meta-analysis.Annals of hematology · 2026Pooled it
- Trial
- Thrombotic burden and longitudinal outcomes in Thai patients with polycythemia vera.Annals of medicine · 2026Article
- Extensive bilateral pulmonary embolism revealing iron deficiency-masked JAK2-positive polycythemia vera: A case report.Radiology case reports · 2026Article
- A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib.Blood advances · 2026Article
- A Therapeutic Dilemma: Catastrophic ST-Elevation Myocardial Infarction Following Antiplatelet Therapy Interruption in a Patient With JAK2-Positive Polycythemia Vera.Clinical case reports · 2026Article
- Complete Hematological Response Coupled with Molecular Response in Polycythemia Vera Treatment with Ropeginterferon Alfa-2b.Life (Basel, Switzerland) · 2026Article
- Prevalence, incidence, and risk factors of secondary malignancies in patients with polycythemia vera: a real-world study.Blood advances · 2026Article
- Risk of thromboembolic events in patients with polycythaemia vera: a study based on german health claims data.Annals of hematology · 2026Article
- Diagnostic and prognostic biomarkers in heart failure and myeloproliferative neoplasms: clinical applications and risk scores - a narrative review.Cardio-oncology (London, England) · 2026Review
- Prognostic Scores and Risk Stratification of Myeloproliferative Neoplasms: 2026 Updates.Cancers · 2026Review
- Modern and multidisciplinary care in polycythemia vera.Annals of hematology · 2026Review
- Complex Aortic Plaques and Polycythemia Vera Presenting as Blue Toe Syndrome Without Peripheral Arterial Disease.JACC. Case reports · 2026Article
- Cardioembolic ST-Elevation Myocardial Infarction in a Patient With Atrial Fibrillation and Polycythemia Vera.Cureus · 2026Article
- Long-term real-world thrombotic and clinical outcomes in polycythemia vera - a hospital-based i2b2 cohort study.Annals of hematology · 2026Article
- Validation and interpretation of the Triple A model in Turkish myeloproliferative neoplasm patients with a focus on overall and thrombosis free survival.Journal of hematopathology · 2025Article
- Exploring Transient Acute Respiratory Distress in Cholera: A Case Series.Clinical case reports · 2025Article
- Evaluation of factors underlying differences in venous thromboembolism rates between Black and White patients.Journal of vascular surgery. Venous and lymphatic disorders · 2025Article
- Article
- Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design.Annals of hematology · 2025Review
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thromboembolic events and cardiovascular disease are the most prevalent complications in patients with polycythemia vera (PV) compared with other myeloproliferative disorders and are the major cause of morbidity and mortality in this population. Moreover, a vascular complication such as arterial or venous thrombosis often leads to the diagnosis of PV. The highest rates of thrombosis typically occur shortly before or at diagnosis and decrease over time, probably due to the effects of treatment. Important risk factors include age (≥ 60 years old) and a history of thrombosis; elevated hematocrit and leukocytosis are also associated with an increased risk of thrombosis. The goal of therapy is to reduce the risk of thrombosis by controlling hematocrit to < 45%, a target associated with reduced rates of cardiovascular death and major thrombosis. Low-risk patients (< 60 years old with no history of thrombosis) are managed with phlebotomy and low-dose aspirin, whereas high-risk patients (≥ 60 years old and/or with a history of thrombosis) should be treated with cytoreductive agents. Interferon and ruxolitinib are considered second-line therapies for patients who are intolerant of or have an inadequate response to hydroxyurea, which is typically used as first-line therapy. In this review, we discuss factors associated with thrombosis and recent data on current treatments, including anticoagulation, highlighting the need for more controlled studies to determine the most effective cytoreductive therapies for reducing the risk of thrombosis in patients with PV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.